Lilly and Novo Nordisk Present GLP-1 Data Suggesting Slowed Biological Aging
Start here
At the Aging Research and Drug Discovery meeting (ARDD) held at Harvard in Boston from October 1–3, 2026, Eli Lilly and Novo Nordisk presented unpublished clinical data suggesting GLP-1 drugs such as semaglutide and tirzepatide slow molecular markers of aging. Lilly reported exploratory results from a SURMOUNT-5 substudy of 71 paired samples showing that 72 weeks of tirzepatide moved all 15 epigenetic clock readings toward younger readings, two reaching significance, with median improvements of 1.1 and 0.7 years. Novo's semaglutide data showed lower mortality, better physical function, and modeled life-expectancy gains. None of the findings are peer-reviewed, and whether the effect comes from weight loss rather than the drugs themselves remains an open question.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comLilly SURMOUNT-5 Substudy Shows Tirzepatide Shifts Epigenetic Clocks Toward Younger Readings at 72 Weeks
At the ARDD conference in October 2026, Lilly presented exploratory data from a SURMOUNT-5 substudy of 71 paired samples, showing that 72 weeks of tirzepatide treatment moved all 15 epigenetic clock readings toward a younger direction, with two reaching significance and median improvements of 1.1 years and 0.7 years. The presentation signals that GLP-1 competition is extending beyond glucose and weight effects, while in China the market is shifting toward competition on distribution capability, pricing strategy and indication coverage.
- reddit.comGLP-1s show signs of slowing biological ageing, say drugmakers
Novo Nordisk and Eli Lilly presented data at the ARDD 2026 ageing research conference at Harvard (October 1–3) suggesting GLP-1 drugs such as semaglutide and tirzepatide can turn back "ageing clock" measures by roughly 2–3 years, according to an MIT Technology Review report of October 6. The presentations cited SELECT and SURMOUNT-5 but have not been peer-reviewed, and the ageing-clock findings are preliminary and hypothesis-generating. A key open question is whether the effect comes from weight loss rather than the drugs themselves.
- mp.weixin.qq.comEli Lilly and Novo Nordisk Present GLP-1 Survival and Function Data at ARDD
At this year's Aging Research and Drug Discovery meeting (ARDD) in Boston, held October 1 to 3, Eli Lilly and Novo Nordisk presented survival and physical-function data on GLP-1 medicines, suggesting anti-aging and longevity potential beyond weight loss. Class-effect evidence was said to point toward broader longevity potential, while semaglutide-specific data showed lower mortality, better physical function, and modeled gains in life expectancy. Both companies' reports carried substantial caveats.
- mp.weixin.qq.comLilly and Novo Nordisk Find GLP-1 Drugs Slow Molecular Markers of Aging
Eli Lilly and Novo Nordisk report that patients taking their GLP-1 drugs for overweight or diabetes aged more slowly than placebo patients, according to molecular "aging clock" readings. Both companies found biological age was reduced with GLP-1 treatment, though the difference varied greatly depending on the type of clock and the organ tested.
- mp.weixin.qq.comNovo and Lilly Present GLP-1 Anti-Aging Data at Harvard ARDD, Claiming 1.1 Years Younger in 72 Weeks
At the 2026 Harvard ARDD meeting, Novo Nordisk and Eli Lilly presented unpublished clinical data positioning GLP-1 receptor agonists as longevity drugs, moving beyond the open question raised at the 2023 meeting. A presented conclusion was that semaglutide and other GLP-1 receptor agonists may support healthier aging, with evidence spanning survival, physical function and a class effect. A headline claim was 1.1 years of biological age reduction over 72 weeks.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 05:00)·Change over 24h in the comparable set +169%
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.